SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135702916> ?p ?o ?g. }

Showing items 1 to 100 of ±188 with 100 items per page.

W3135702916 endingPage "2353" @default.
W3135702916 startingPage "2337" @default.
W3135702916 abstract "This systematic review evaluates the efficacy and safety of biologicals for chronic rhinosinusitis with nasal polyps (CRSwNP) compared with the standard of care. PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CRSwNP-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. RCTs evaluated (dupilumab-2, omalizumab-4, mepolizumab-2, and reslizumab-1) included 1236 adults, with follow-up of 20-64 weeks. Dupilumab reduces the need for surgery (NFS) or oral corticosteroid (OCS) use (RR 0.28; 95% CI 0.20-0.39, moderate certainty) and improves with high certainty smell evaluated with UPSIT score (mean difference (MD) +10.54; 95% CI +9.24 to +11.84) and quality of life (QoL) evaluated with SNOT-22 (MD -19.14; 95% CI -22.80 to -15.47), with fewer treatment-related adverse events (TAEs) (RR 0.95; 95% CI 0.89-1.02, moderate certainty). Omalizumab reduces NFS (RR 0.85; 95% CI 0.78-0.92, high certainty), decreases OCS use (RR 0.38; 95% CI 0.10-1.38, moderate certainty), and improves high certainty smell (MD +3.84; 95% CI +3.64 to +4.04) and QoL (MD -15.65; 95% CI -16.16 to -15.13), with increased TAE (RR 1.73; 95% CI 0.60-5.03, moderate certainty). There is low certainty for mepolizumab reducing NFS (RR 0.78; 95% CI 0.64-0.94) and improving QoL (MD -13.3; 95% CI -23.93 to -2.67) and smell (MD +0.7; 95% CI -0.48 to +1.88), with increased TAEs (RR 1.64; 95% CI 0.41-6.50). The evidence for reslizumab is very uncertain." @default.
W3135702916 created "2021-03-15" @default.
W3135702916 creator A5006674601 @default.
W3135702916 creator A5012215238 @default.
W3135702916 creator A5016086834 @default.
W3135702916 creator A5016655950 @default.
W3135702916 creator A5019798684 @default.
W3135702916 creator A5019919684 @default.
W3135702916 creator A5023964068 @default.
W3135702916 creator A5026307267 @default.
W3135702916 creator A5026672365 @default.
W3135702916 creator A5029784499 @default.
W3135702916 creator A5030244193 @default.
W3135702916 creator A5033290575 @default.
W3135702916 creator A5033323865 @default.
W3135702916 creator A5034364156 @default.
W3135702916 creator A5034770022 @default.
W3135702916 creator A5038444881 @default.
W3135702916 creator A5041432706 @default.
W3135702916 creator A5044974328 @default.
W3135702916 creator A5055404517 @default.
W3135702916 creator A5055891096 @default.
W3135702916 creator A5064053640 @default.
W3135702916 creator A5069953857 @default.
W3135702916 creator A5072905963 @default.
W3135702916 creator A5074241836 @default.
W3135702916 creator A5075963361 @default.
W3135702916 creator A5079387252 @default.
W3135702916 creator A5080292717 @default.
W3135702916 creator A5084313111 @default.
W3135702916 creator A5084613159 @default.
W3135702916 creator A5090361830 @default.
W3135702916 date "2021-03-24" @default.
W3135702916 modified "2023-10-18" @default.
W3135702916 title "Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines" @default.
W3135702916 cites W1484430174 @default.
W3135702916 cites W1537778055 @default.
W3135702916 cites W1591052090 @default.
W3135702916 cites W1788289044 @default.
W3135702916 cites W1963621226 @default.
W3135702916 cites W1968876836 @default.
W3135702916 cites W1997889941 @default.
W3135702916 cites W2002980147 @default.
W3135702916 cites W2010149513 @default.
W3135702916 cites W2042287272 @default.
W3135702916 cites W2067989180 @default.
W3135702916 cites W2091662896 @default.
W3135702916 cites W2095499340 @default.
W3135702916 cites W2098923148 @default.
W3135702916 cites W2105880697 @default.
W3135702916 cites W2109346853 @default.
W3135702916 cites W2141663349 @default.
W3135702916 cites W2165010366 @default.
W3135702916 cites W2428069039 @default.
W3135702916 cites W2462860861 @default.
W3135702916 cites W2507811495 @default.
W3135702916 cites W2596290339 @default.
W3135702916 cites W2607459356 @default.
W3135702916 cites W2730614382 @default.
W3135702916 cites W2748830120 @default.
W3135702916 cites W2767476962 @default.
W3135702916 cites W2805638549 @default.
W3135702916 cites W2810779501 @default.
W3135702916 cites W2920951015 @default.
W3135702916 cites W2931887819 @default.
W3135702916 cites W2939825951 @default.
W3135702916 cites W2945257869 @default.
W3135702916 cites W2973437633 @default.
W3135702916 cites W2983079501 @default.
W3135702916 cites W2998354760 @default.
W3135702916 cites W3009850785 @default.
W3135702916 cites W3011782337 @default.
W3135702916 cites W3014800880 @default.
W3135702916 cites W3014934509 @default.
W3135702916 cites W3023552461 @default.
W3135702916 cites W3029422723 @default.
W3135702916 cites W3034146395 @default.
W3135702916 cites W3084176537 @default.
W3135702916 cites W3087589594 @default.
W3135702916 cites W3087770431 @default.
W3135702916 cites W3088337584 @default.
W3135702916 cites W3096206487 @default.
W3135702916 cites W3097250921 @default.
W3135702916 cites W3109149460 @default.
W3135702916 cites W31716537 @default.
W3135702916 doi "https://doi.org/10.1111/all.14809" @default.
W3135702916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33683704" @default.
W3135702916 hasPublicationYear "2021" @default.
W3135702916 type Work @default.
W3135702916 sameAs 3135702916 @default.
W3135702916 citedByCount "65" @default.
W3135702916 countsByYear W31357029162021 @default.
W3135702916 countsByYear W31357029162022 @default.
W3135702916 countsByYear W31357029162023 @default.
W3135702916 crossrefType "journal-article" @default.
W3135702916 hasAuthorship W3135702916A5006674601 @default.
W3135702916 hasAuthorship W3135702916A5012215238 @default.
W3135702916 hasAuthorship W3135702916A5016086834 @default.